Cytocom, Inc. (CBLI) Stock

About Cytocom, Inc.

Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.

Cytocom, Inc. is headquartered in US.

Cytocom, Inc. (CBLI) stock trades at $3.17 with a market capitalization of $226.39M. The stock is valued at a price-to-earnings (P/E) ratio of -16.68, price-to-book of 19.52, price-to-sales of 860.98. Over the past 52 weeks the stock has ranged between $2.70 and $5.64, and currently trades 43.8% below its 52-week high.

On profitability, Cytocom, Inc. generates a return on equity (ROE) of -160.02%, return on capital employed of -128.47%, an operating margin of -983.70%, a net profit margin of -912.16%.

Official website: www.cytocom.com